HER-096
Asset
CDNF peptidomimetic alleviating proteostatic stress and supporting dopaminergic neuron survival.
- Stage
- Phase 1
- Modality
- Peptide
- Target
- Proteostasis
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Idiopathic Parkinson disease
Phase 1, Completed, NCT06659562, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Trials1
- Evidence for its targets2
- Competitors1
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026, 1 source